Quick facts
- An at-home respiratory test kit is an in vitro diagnostic device used by a lay person, not by a laboratory professional. That single sentence decides most of its regulation.
- United States: 21 CFR 866.3984 names the over-the-counter test to detect SARS-CoV-2 and places it in Class II (special controls), with an intended use built around lay users performing the test "without required health care provider intervention".
- Influenza has its own entry with performance floors: 21 CFR 866.3328 sets minimum clinical performance criteria, including a positive percent agreement point estimate of at least 80 percent for influenza A and B against a cleared comparator.
- The waived-test list is a short list. 42 CFR 493.15 enumerates the tests a certificate-of-waiver laboratory may perform, and an at-home respiratory test is not one of them.
- Canada classifies in vitro diagnostic devices under the Medical Devices Regulations, SOR/98-282, and the laboratory that reports a result is licensed provincially rather than under a single federal laboratory statute.
- Specimen handling is written down on both sides. In the United States 42 CFR 493.1242 requires written policies for collection, labelling, storage, transport and rejection; in Ontario the equivalent discipline comes from provincial laboratory licensing.
A test a patient performs at home looks like a consumer product, which is exactly why the rules matter: a diagnostic result is being generated outside a laboratory, by someone with no training, using a device whose labelling must make the limits of that result clear.
This article sets out what these kits are, how each country classifies them, where the waived-test list fits, and what a programme documents when it hands one out.
What is an at-home respiratory test kit?
Three characteristics define the product.
The user is a lay person. The instructions are the only supervision. The US entry says so in the identification: the device is "intended to be used by lay users and without required health care provider intervention in home settings or similar environments in which lay users perform testing".
The specimen is collected by the same person who runs the test. That is why the US special controls demand evidence that lay users can collect the specimen type without provider supervision.
The result is a screening input, not a diagnosis. A negative antigen result does not exclude infection, and the labelling rules are written to say so.
Buyers meet three families: antigen tests read visually, antigen tests read by a small instrument, and molecular tests run in a cartridge. All three are in vitro diagnostic devices; they differ in sensitivity and in what the labelling may claim.
How does the United States classify an at-home test?
The United States gives these products dedicated entries, and the entries carry special controls rather than only a class.
21 CFR 866.3984 identifies the over-the-counter test to detect SARS-CoV-2 from clinical specimens and classifies it as Class II (special controls). The special controls include three requirements that shape any labelling a buyer will read:
- The intended use must describe "the analytes the device detects and identifies, the specimen types tested, the results provided to the user, the clinical indications for which the test is to be used, the specific intended population(s), and other conditions of use".
- The intended use "must only include indications for testing of respiratory specimens that are appropriate for collection by lay users for which there are performance data that demonstrate lay users can collect specimens without health care provider supervision".
- The labelling must include "a statement in the intended use that positive results do not rule out co-infection with other respiratory pathogens".
21 CFR 866.3328 covers influenza virus antigen detection and is also Class II (special controls). Its identification explains why the performance floor exists: "Due to the propensity of the virus to mutate, new strains emerge over time which may potentially affect the performance of these devices," and because influenza can cause severe illness, "the accuracy of these devices has serious public health implications". The controls require the device's sensitivity and specificity, or positive and negative percent agreement, for each claimed specimen type to meet "one of the following two minimum clinical performance criteria", the first of which sets the positive percent agreement estimate for influenza A and B at "the point estimate of at least 80 percent".
Two neighbouring entries complete the picture: 21 CFR 866.3982, the simple point-of-care device that directly detects SARS-CoV-2 viral targets, and 21 CFR 866.3983, the SARS-CoV-2 serology test — the antibody test, which answers a different question from the antigen test.
Which US tests count as waived?
Very few, and the list is worth reading in full because it shows how narrow the category is.
42 CFR 493.15(b) defines waived test systems as simple examinations and procedures that "(1) Are cleared by FDA for home use; (2) Employ methodologies that are so simple and accurate as to render the likelihood of erroneous results negligible; or (3) Pose no reasonable risk of harm to the patient if the test is performed incorrectly."
Paragraph (c) then enumerates the tests a certificate-of-waiver laboratory may perform and no others: non-automated dipstick or tablet reagent urinalysis for ten named analytes; non-automated fecal occult blood; ovulation tests by visual colour comparison; urine pregnancy tests by visual colour comparison; non-automated erythrocyte sedimentation rate; non-automated hemoglobin by copper sulfate; blood glucose by glucose monitoring devices cleared specifically for home use; spun microhematocrit; and hemoglobin by single analyte instruments with self-contained component features.
An at-home COVID-19 or influenza test is not on that list. It reaches the point of care through its own device entry and its own clearance route, and where a site performs testing outside a certificate of waiver, 42 CFR 493.1242 requires the laboratory to have written policies and procedures for patient preparation, specimen collection, labelling, storage and preservation, conditions of transportation, processing, acceptability and rejection, and referral.
Does Canada classify these kits the same way?
No. Canada classifies in vitro diagnostic devices under the regulations rather than under a named-entry code, and the laboratory end of the chain is licensed provincially.
Three consequences matter in procurement.
The device licence belongs to the product, not the site. An in vitro diagnostic device sold in Canada requires a device licence held by the manufacturer or importer, and a distributor importing devices holds an establishment licence under SOR/98-282.
Laboratory operation is a provincial matter. Ontario licenses laboratories and specimen collection centres under the Laboratory and Specimen Collection Centre Licensing Act, R.S.O. 1990, c. L.1, which is the provincial counterpart of the federal CLIA framework.
Public health reporting runs through the provincial laboratory. Public Health Ontario publishes the test information index entry for COVID-19 PCR testing, which sets out specimen requirements and collection instructions for the provincial laboratory stream. Medical laboratories also commonly work to ISO 15189:2022.
| Item | Canada | United States |
|---|---|---|
| Classification approach | In vitro diagnostic devices classified under the Medical Devices Regulations | Named in vitro diagnostic entries per product code |
| Named entry for an at-home COVID-19 test | No named entry; classified by rule | 21 CFR 866.3984, Class II (special controls) |
| Named entry for an influenza antigen test | No named entry; classified by rule | 21 CFR 866.3328, Class II (special controls) |
| Performance floor in the entry | Not stated in a named entry; assessed with the licence application | Positive percent agreement point estimate of at least 80 percent for influenza A and B |
| Laboratory oversight | Provincial licensing, for example Ontario's Laboratory and Specimen Collection Centre Licensing Act | Federal CLIA, with the waived list in 42 CFR 493.15 |
| Public health testing stream | Provincial laboratory, for example the Public Health Ontario test information index | State and federal public health laboratories plus commercial CLIA laboratories |
CliniEco Medical holds Health Canada MDEL #35334 as an establishment, which is an authorisation to import and distribute devices in Canada. It is not a statement about any individual test kit.
Why does the specimen wording matter so much?
Because the claim about who can collect the specimen is the difference between a product that can be sold over the counter and one that cannot.
The US special controls for the over-the-counter SARS-CoV-2 test permit indications for testing only of "respiratory specimens that are appropriate for collection by lay users", and require performance data showing that lay users can collect those specimens without provider supervision. Whether a person can reliably swab their own nose at home is therefore answered with data in the device file rather than assumed on the label.
Two further labelling duties follow from that logic. The intended use must state what the test detects, which specimen types were tested and which population it was studied in, and it must carry the statement that a positive result does not rule out co-infection with other respiratory pathogens. For a buyer writing a specification for clinic or workplace use, the practical reading is that the label, not the marketing page, defines what the test is allowed to be used for.
| Item | Canada | United States |
|---|---|---|
| Who may collect the specimen | Provincial collection-centre rules and the device's instructions for use | Only specimen types in the intended use that are appropriate for lay collection |
| Labelling duties | Set by the device licence and the applicable labelling requirements | Special controls listing analytes, specimen types, results, indications and population |
| Co-infection wording | Not prescribed in a named entry | Required statement that positive results do not rule out co-infection |
| Transport of specimens to a laboratory | Provincial requirements plus federal dangerous goods rules for specimen transport | 42 CFR 493.1242 policies, plus transport rules for the specimen category |
| Reporting route | Provincial public health laboratory and provincial reporting duties | State and federal reporting duties |
What does a programme document when it dispenses self-tests?
A self-test that leaves the building still generates obligations. Four records carry them.
The kit record. Which device, lot and expiry were issued, plus the instructions that went with them, because a result is only interpretable against the device that produced it.
The instruction step. The person receiving the kit needs to know what a negative result means and what to do about a positive one. That conversation is why a programme exists rather than a box of kits in a cupboard.
The return pathway. Where a specimen or a result comes back to a professional setting, that setting's collection and transport rules apply, and 42 CFR 493.1242 is the checklist of what a laboratory must have in writing.
The waste pathway. Used components, packaging and specimen material are waste, and the segregation decision belongs in the written procedure.
Which consumables does a testing programme consume?
- Specimen transport. UN3373 specimen transport bags carry the primary receptacle, with 3-wall leak-resistant transport bags as the secondary layer.
- Hand contact. Nitrile examination gloves are consumed by staff handling kits, specimens and waste.
- Respiratory protection for staff. A collection station is a close-contact setting, and 3-ply ASTM Level 3 masks are stocked for it.
- Waste segregation. Biohazard waste bags keep the segregation decision visible.
Sources
- 21 CFR 866.3984, over-the-counter test to detect SARS-CoV-2
- 21 CFR 866.3328, influenza virus antigen detection test system
- 21 CFR 866.3982, simple point-of-care SARS-CoV-2 device
- 21 CFR 866.3983, SARS-CoV-2 serology test
- 21 CFR 866.2390, transport culture medium
- 21 CFR 866.2900, microbiological specimen collection and transport device
- 42 CFR 493.15, laboratories performing waived tests
- 42 CFR 493.1242, specimen submission, handling and referral
- 42 CFR 493.5, categories of tests by complexity
- Medical Devices Regulations, SOR/98-282
- Ontario, Laboratory and Specimen Collection Centre Licensing Act
- Public Health Ontario, COVID-19 test information
- Public Health Ontario, test information index
- Public Health Ontario, criteria for acceptance of specimens
- ISO 15189:2022, requirements for quality and competence in medical laboratories
- ISO 6710:2017, single-use blood specimen containers
- CLSI, order of draw for blood collection tubes
- WHO, antimicrobial resistance
- CCOHS, personal protective equipment
- Health Canada, medical device guidance documents
Ordering for a clinic, laboratory or care home? Wholesale and multi-site ordering covers account setup and case pricing, and the B2B wholesale collection lists the lines stocked for institutional buyers. Clinics that also run an in-house sterilizer can start with the biological indicator 5-pack trial.
Related reading
- Nasopharyngeal swabs in Canada vs the US: which collection rules apply
- Rapid strep tests in Canada vs the US: which rules change
- EDTA tubes in Canada vs the US: which draw rules apply
- 24-hour urine collection in Canada vs the US: which container rules apply
- Blood culture bottles in Canada vs the US: which rules apply
Frequently Asked Questions
Is an at-home COVID-19 test a waived test in the United States?
It is not on the waived-test list in 42 CFR 493.15, paragraph (c) of which names a short set of tests such as non-automated urinalysis, urine pregnancy tests and blood glucose devices cleared for home use. An at-home respiratory test reaches the user through its own device entry and clearance.
What performance does the US expect from an influenza antigen test?
21 CFR 866.3328 requires the device's sensitivity and specificity, or positive and negative percent agreement, for each claimed specimen type to meet one of two minimum clinical performance criteria. The first sets the positive percent agreement point estimate for influenza A and B at no less than 80 percent against a cleared comparator that is not viral culture.
Why does the labelling have to mention co-infection?
Because a positive result on a respiratory test does not exclude another pathogen being present at the same time. The US special controls for the over-the-counter SARS-CoV-2 test require a statement in the intended use that positive results do not rule out co-infection with other respiratory pathogens.
Does Canada have a separate entry for a COVID-19 self-test?
No. Canada classifies in vitro diagnostic devices under the Medical Devices Regulations rather than by named product entry, and a device sold in Canada carries a device licence held by the manufacturer or importer. The laboratory that reports results is licensed provincially, which is why the Ontario laboratory statute and the Public Health Ontario test information index are the documents a programme actually works from.
Who can collect the specimen for one of these tests?
The device's intended use defines which specimen types a lay user may collect, and the US special controls require performance data showing lay users can collect them without supervision. Where a specimen is collected in a professional setting instead, the governing rules are those of the receiving laboratory, including written collection and transport policies.
What should a workplace document when it hands out test kits?
The device, lot and expiry issued; the instruction given on what a result means and what to do next; the pathway by which a specimen or result returns to a professional setting; and the waste segregation procedure for used components and packaging. Those four records are what make a self-test programme auditable.
CliniEco Medical supplies laboratory and specimen handling consumables described in this article. Health Canada MDEL #35334. This article is written for clinic, laboratory and procurement professionals and is not clinical guidance; test interpretation and reporting decisions belong to the treating practitioner.
0 comments